A Day Up For Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. (TRVI:NASDAQ) shot up at $1.15, representing a gain of 32%. On Tue, Mar 01, 2022, TRVI:NASDAQ hit a New 2-Week High of $0.87. The stock appeared on our News Catalysts scanner on Thu, Feb 24, 2022 at 08:17 AM in the 'BIOTECH' category. From Wed, Feb 16, 2022, the stock recorded 62.50% Up Days and 55.56% Green Days
About Trevi Therapeutics, Inc. (TRVI:NASDAQ)
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. It is involved in developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, and levodopa-induced dyskinesia, or LID, in patients with Parkinson's disease.
Top 10 Gainers:
- ECMOHO Limited (MOHO:NASDAQ), 56.65%
- Imperial Petroleum Inc. (IMPP:NASDAQ), 39.19%
- Nordstrom, Inc. (JWN:NYSE), 37.82%
- Regulus Therapeutics Inc. (RGLS:NASDAQ), 35.56%
- Indonesia Energy Corporation Limited (INDO:NYSEMKT), 34.51%
- Trevi Therapeutics, Inc. (TRVI:NASDAQ), 32.02%
- Arlo Technologies, Inc. (ARLO:NYSE), 28.92%
- Rocky Brands, Inc. (RCKY:NASDAQ), 26.59%
- China SXT Pharmaceuticals, Inc. (SXTC:NASDAQ), 26.07%
- Universal Security Instruments, Inc. (UUU:NYSEMKT), 25.89%